8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 9, 2026·SEC
Cardiff Oncology, Inc.(CRDF)Earnings, Financials & Key Ratios
CRDF•NASDAQ
$1.30
Price updated Jul 6, 2026
AboutCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Show more
- Revenue$593K-13.2%
- EBITDA-$48M+0.4%
- Net Income-$46M-0.9%
- EPS (Diluted)-0.69+27.4%
- Gross Margin100%
- EBITDA Margin-8103.88%-14.7%
- Operating Margin-8256.32%-15.9%
- Net Margin-7732.04%-16.2%
- ROE-71.45%-20.1%
CRDF Price & Volume
Cardiff Oncology, Inc. (CRDF) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Cardiff Oncology Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding insolvency
Key Thesis Takeaways
- Cardiff Oncology remains a high-risk, pre-commercial biotechnology firm characterized by a lack of sustainable revenue and a heavy reliance on equity-based financing to fund its clinical pipeline.
- The company's financial trajectory is defined by deep operating losses, with R&D expenditures of $6.8 million in 2026Q1 consistently outpacing its minimal $41,000 revenue base.
- Investors should monitor the rapidly depleting cash position, which fell to $8.5 million in 2026Q1, as the firm faces significant liquidity constraints that may necessitate further dilutive capital raises.
Verdict Logic
the company's cash runway is critically low at $8.5 million against a quarterly operating loss of $12.8 million, signaling an urgent need for dilutive financing.
CRDF Growth Metrics
Cardiff Oncology, Inc. (CRDF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.6%
5 Years10.13%
3 Years15.39%
TTM-10.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.58%
Return on Capital
10 Years-81.13%
5 Years-48.42%
3 Years-63.04%
Last Year-75.76%
CRDF Recent Earnings
Cardiff Oncology, Inc. (CRDF) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.18-38.5%
$0.13
Rev
$41,000-53.7%
$88,571
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.11+38.9%
$0.18
Rev
$243,000+134.8%
$103,500
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.17+15.0%
$0.20
Rev
$120,000+15.9%
$103,500
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.21-10.5%
$0.19
Rev
$121,000+10.6%
$109,375
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.18vs $0.13-38.5% | $41,000vs $88,571-53.7% |
| Q1 2026 | Feb 24, 2026 | $0.11vs $0.18+38.9% | $243,000vs $103,500+134.8% |
| Q4 2025 | Nov 6, 2025 | $0.17vs $0.20+15.0% | $120,000vs $103,500+15.9% |
| Q3 2025 | Jul 29, 2025 | $0.21vs $0.19-10.5% | $121,000vs $109,375+10.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Cardiff Oncology, Inc. (CRDF)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $88.88M | -1.88 | -13.18% | -7732.04% | -71.45% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $9.62 | $82.13M | -0.54 | 0.57% | -129.02% | — | — |
Compare CRDF vs Peers
Cardiff Oncology, Inc. (CRDF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRDF SEC Filings & Documents
Cardiff Oncology, Inc. (CRDF) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CRDF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRDF Frequently Asked Questions
Cardiff Oncology, Inc. (CRDF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cardiff Oncology, Inc.'s revenue?
Cardiff Oncology, Inc. (CRDF) reported $0.5M in revenue for fiscal year 2025.
How fast is Cardiff Oncology, Inc. growing?
Cardiff Oncology, Inc. (CRDF) saw revenue decline by 13.2% over the past year.
Is CRDF profitable?
Cardiff Oncology, Inc. (CRDF) reported a net loss of $44.8M for fiscal year 2025.
Dividend & Returns
What is CRDF's return on equity?
Cardiff Oncology, Inc. (CRDF) has a return on equity (ROE) of -71.5%. Negative ROE indicates the company is unprofitable.
What is Cardiff Oncology, Inc.'s free cash flow?
Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $37.5M in fiscal year 2025, likely due to heavy capital investments.